Indivior is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity.
Our commitment is unwavering: to expand access to effective treatment, dismantle stigma, and empower every person living with OUD to define their lives beyond the disease.
Indivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the matter.
We partner with scientists, communities, clinicians, policymakers, people living with OUD, and caregivers to advance access to evidence-based treatment for OUD, dismantle stigma, and elevate the lived experience of individuals in recovery. Together, we are advancing recovery for OUD — one life, one family, and one community at a time.